DEM BioPharma

DEM BioPharma is an immuno-oncology company dedicated to eradicating cancer by targeting novel innate immune system checkpoints. DEM Bio is a pioneer in next-generation immunotherapeutics aimed at unleashing macrophages and other myeloid effector cells to eliminate tumors by targeting novel “Don’t Eat Me” (DEM) and “Eat Me” (EM) signals on both cancer cells and macrophages. The company’s proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) will be used to identify untapped DEM and EM signals in a systematic and unbiased manner through intercellular CRISPR screens utilizing tumor cells, primary macrophages, and other innate immune effector cells.